A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Investigators assessed whether intravesical BCG is necessary for patients with high-grade T1 nonmuscle-invasive bladder cancer who have unremarkable histology on the second transurethral resection.

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, ...

There are about 80,000 new cases of bladder cancer every year in the US alone. About one-third of cases are diagnosed at late ...

The risks of adverse effects and complications from treatment for prostate cancer are substantial and continue for years after treatment ends.

Rashid Sayyid and Zach Klaassen discuss a study published in Lancet Oncology titled, “Radical Cystectomy versus Trimodality Therapy for Muscle-Invasive Bladder Cancer: A Multi-Institutional Propensity ...

Department of Gynecological Oncology and National Clinical Research Center for Obstetrics and Gynecology, Cancer Biology Research Center (Key Laboratory of the Ministry of Education), Tongji Hospital, ...

Oct. 24, 2024 – The FDA has approved a new drug called zolbetuximab designed to attack a novel target that’s in a type of stomach cancer. Marketed under the brand name Vyloy, the drug is to ...

Botox is a prescription drug that’s used to treat certain bladder problems, such as overactive bladder (OAB) in adults. For certain bladder problems, Botox may also be prescribed to children ...

Female bladder cancer patients undergoing bladder-sparing therapies often experience minimal disruption to sexual health compared to those undergoing cystectomy. The study underscores the need for ...

Gilead is with­draw­ing the ac­cel­er­at­ed ap­proval for its block­buster an­ti­body-drug con­ju­gate Trodelvy for blad­der can­cer af­ter it failed to im­prove sur­vival odds ...